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ABSTRACT   
Chlamydia serology is indicated to investigate etiology of miscarriage, infertility, PID and 
ectopic pregnancy. Here, we assessed the reliability of a new automated-multiplex 
immunofluorescence assay (InoDiag test) to detect specific anti-C. trachomatis IgG. 
Considering IF as gold standard, InoDiag tests exhibited similar sensitivities (65.5%), but better 
specificities (95.1%-98%) than ELISAs. InoDiag tests demonstrated similar or lower cross-
reactivity rates when compared to ELISA or IF. 
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INTRODUCTION 
Prevalence of Chlamydia trachomatis genital infections is steadily increasing over the last 
decade (Rekart et al., 2013). The majority of chlamydial infections remain asymptomatic and 
therefore undetected causing a worldwide silent epidemic (Paavonen, 2012). Left untreated, 
Chlamydia trachomatis may lead to ascending infection and tubal damage with chronic sequelae 
such as tubal infertility and sterility (Baud and Greub, 2011; Paavonen, 2012). Moreover, 
Chlamydia trachomatis is recognised as an agent of miscarriage (Baud et al., 2011). Although 
PCR represents the ideal diagnostic approach for uretritis and cervicitis, serology remains useful 
to detect anti-chlamydial antibodies among women with tubal infertility, ectopic pregnancy, 
miscarriage, pelvic inflammatory disease and chronic pelvic pain (Baud et al., 2008; Baud et al., 
2011; Baud and Greub, 2011; Haggerty et al., 2010), since in such chronic conditions, the 
negative predictive value is very high. Microimmunofluorescence assay (IF), still considered as 
the “gold standard” for the serology of this pathogen, has the disadvantage to be time-
consuming, subjective and reader-dependant (Gaydos C and Essig A, 2011). However, enzyme-
linked immunosorbent assays (ELISA) using the major outer membrane protein (MOMP) as 
antigen appears to exhibit a higher sensitivity for diagnosing chlamydial infections (Baud et al., 
2010). 
The present study aimed to investigate the performance of a new fully automatized “multiplex 
fluorescence immuno-assay” (Inodiag®, Signes, France) to detect specific anti-C. trachomatis 
IgG. Two different assay formats were investigated: Inodiag-EBs based on antibody reactivity to 
the elementary body (EB) and Inodiag-MOMP based on the MOMP of chlamydiae. Both 
Inodiag tests were compared with two other commercialized MOMP ELISA tests (MOMP-
Medac® and MOMP-RBiopharm®) and to IF, which was considered to be the the gold standard. 
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METHOD 
Studied sera were obtained from women with and without miscarriages as described previously 
by Baud et al. (Baud et al., 2007; Baud et al., 2009; Baud et al., 2010). A total of 265 sera were 
tested for the presence of Chlamydia trachomatis IgG antibodies with the new automated 
“multiplexed serology test” (Mu.S.T) as previously described (Baud et al., 2010; Gouriet et al., 
2008a; Gouriet et al., 2008b), but using a new InoDiag platform allowing simultaneous testing 
of up to 12 patients in a single run. Practically, 2 different Chlamydia trachomatis antigens are 
present in the test: elementary bodies (InoDiag-EB) and MOMP (InoDiag-MOMP). Results of 
EBs and MOMP antigens were analysed separately and combined (hereafter called InoDiag-
Combi, see details in Table 1).  
Inodiag tests were compared with 3 other serological tests: immunofluorescence (Micro IF, 
ANILabsystems, Vantaa, Finland) and two C. trachomatis IgG ELISA both using the MOMP as 
antigen: MOMP-Medac, CT-IgG-pELISA, Medac, Webel, Germany and MOMP-R, CT 
pELISA, R-Biopharm, Darmstadt, Germany. All these 3 commercial tests were performed 
according to the manufacturers’ instructions.  
To evaluate cross-reactivity, serum samples collected from patients with positive serologies 
against Toxoplasma gondii (n=81 cases), Waddlia chondrophila (n=83), Chlamydia psittaci 
(n=24), Chlamydia pneumoniae (n=96) and Brucella sp (n=11) were also analysed and the risk 
of cross-reactivity with Chlamydia trachomatis was statistically determined. All these 
serological tests were performed using commercial kits previously reported (Baud et al., 2007, 
Baud et al., 2010) and for Waddlia chondrophila using an home made immunofluorescence as 
earlier described (Baud et al., 2007). 
To compare all five serological tests, the sensitivities, specificities, positive predictive values 
(PPVs) and negative predictive values (NPVs) were calculated using Stata (StataCorp, College 
Station, TX, USA). Values in the grey zone (i.e. with optical densities between the values 
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threshold for negativity and positivity, as defined by the manufacturer of MOMP-Medac and 
MOMP-RB) were excluded from these analyses. To assess cross-reactivity, we compared the 
correlation between serology directed against two different pathogens using the Chi2 test. 
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RESULTS 
Of the 265 sera, Chlamydia trachomatis IgG seropositivity rate was 14%, 19%, 16%, 11%, 13% 
and 9% with IF, MOMP-Medac, MOMP-RB, InoDiag-EB, InoDiag-MOMP and InoDiag-
Combi, respectively. Inconclusive results were respectively observed in 0%, 3%, 7%, 2%, 3% 
and 10% of these serological tests. The level of agreement between the assays was similar. The 
percentage of concordance with results of IF was 63.9% for MOMP-Medac, 61.1% for MOMP-
RBiopharm, 63.9% for Inodiag-EBs, 63.9% for MOMP and 55.6 % for Inodiag-Combi. 
Table 1 shows performance of the different assay using IF as gold standard. A total of 33 
inconclusive samples (12%) were excluded from the inter-assays comparison as they exhibited a 
doubtful result by at least one assay. MOMP-RB and InoDiag-Combi exhibited the best 
sensitivities (72.4%), whereas InoDiag-EB exhibited the best specificity (98%). 
A second analysis was conducted using a modified gold standard based on the results from IF, 
MOMP-Medac and MOMP-RB (see footnotes of Table 1 for details). This analysis involved 
197 samples including 17 Chlamydia trachomatis-positive and 177 Chlamydia trachomatis-
negative samples. InoDiag-MOMP and InoDiag-Combi exhibited the best sensitivities (100%), 
whereas InoDiag-EB exhibited the best specificity (99.4%). 
All 6 tests cross-reacted with C. psittaci (p<0.001) and C. pneumoniae (p<0.05 – 0.001) as 
shown in Table 2. Moreover, IF also cross-reacted significantly with T. gondii and W. 
chondrophila (Table 1). InoDiag-MOMP showed the lowest cross-reactivity rate, with the 
different investigated species. 
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DISCUSSION  
In this study, we assessed the performance of an automated multiplex antigen microarray 
(InoDiag) for the detection of Chlamydia trachomatis IgG antibodies.  
The specificity of the Inodiag assays (94.6%-98%) was higher than the two commercialized 
ELISA used for comparison, whereas sensitivities were similar (65.5%-72.4%). In the present 
study, we showed that sensitivity was not improved by MOMP alone compared to EBs. 
However, the combination of MOMP and EBs by Inodiag increased sensitivity without altering 
specificity. All the tests studied here show low PPV, indicating that confirmation is required 
when positive as suggested by others (Mylonas, 2012). Moreover, we would recommend to use 
a second serological assay in case of doubtful result (grey zone). 
The “gold standard” IF exhibits significant limitations: (i) high levels of cross-reactions with 
other members of the Chlamydiacae family, (ii) labour-intensive and (iii) subjective and 
operator-dependant reading. In contrast, ELISAs (Medac or R-Biopharm) represent a test 
characterized by the following advantages: (i) objective reading of the results, (ii) less expensive 
than IF (especially when considering technician time) and (iii) high throughput, useful for 
epidemiological studies.  
In contrast to our study, Muvunyi et al. showed that peptide-based ELISA performed as well as 
two different IF assays (Muvunyi et al, 2012). However, the performance of the InoDiag tests 
presented here are consistent with previous studies that revealed good sensitivities and 
specificities of ELISA assays based on peptides from the MOMP (Muvunyi et al, 2012 ; Land 
JA et al, 2003).The new automated microarray from Inodiag® show similar performance than 
ELISA. It is well designed for small laboratories, since batches of only 2 to 4 samples can be 
tested with InoDiag. Several pathogens can be tested simultaneously, allowing pathology-driven 
testing instead of the common pathogen-driven testing (Gouriet et al., 2008a; Gouriet et al., 
2008b; Raoult et al., 2004). Moreover, thank to the multiplex format of the Inodiag technology, 
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new markers of chronic C. trachomatis infection might be added to improve serodiagnosis 
(Cappello et al., 2009).  
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Table 1-bis: Performance of the 3 INODIAG serological tests using a new gold standard(1).  1	  
The 95% confidence intervals are shown in brackets. 2	  
 3	  
Assay 
 
Sensitivity 
 
Specificity 
 
PPV NPV 
        
INODIAG - EBs 
 
89.5% [66.9-98.7] 
 
99.4% [96.9-100] 
 
94.4%[72.7-99.9] 98.9% [96-99.9] 
INODIAG-MOMP 100% [82.4-100] 97.2% [93.5-99.1] 79.2% [57.9-92.9] 100% [97.9-100] 
INODIAG-Combi*  100% [82.4-100]  96.6% [92.8-98.8]  76% [54.9-90.6] 100% [97.9-100] 
 4	  
 5	  
*InoDiag-Combi was designed according to the results of InoDiag-EB and InoDiag-MOMP. 6	  
True positives were defined as both tests positive and true negatives as both tests negative. 7	  
Discordant results or values in the grey zone were excluded from the analysis.  8	  
 9	  
 (1) Performance of the tests using a new gold standard based on the results of IF, MOMP-Medac 10	  
and MOMP-RB. True positives were defined as all 3 tests positive and true negatives as all 3 11	  
tests negative. All discordant results or results in the grey zone were excluded from the analysis. 12	  
Table 2:  Rate of Chlamydia trachomatis positivity of each serological assay for sera 1	  
identified IgG-positive for another pathogenic agent.  2	  
 3	  
Assay 
 
Toxoplasma 
gondii 
n=81 
Waddlia 
chondrophila 
n=83 
Chlamydia 
psittaci 
n=24 
Chlamydia 
pneumoniae 
n=96 
Brucella 
abortus 
n=11 
IF 21% [12-30] (+) 7% [2-13] (+) 79% [62-97] (+++) 27% [18-36] (+++) 9% [0-29] 
MOMP-Medac 15% [7-23] 16% [8-24] 67% [46-87] (+++) 29% [20-38] (++) 9% [0-29] 
MOMP-RBiopharm 14% [6-21] 13% [6-21] 71% [51-90] (+++) 30% [21-40] (+++) 9% [0-29] 
 
     
INODIAG - EBs  12% [5-20] 6% [1-11] 79% [62-97] (+++) 20% [12-28] (++) 0% [0-0] 
INODIAG-MOMP 11% [4-18] 11% [4-18] 67% [46-87] (+++) 20% [12-28] (+) 0% [0-0] 
INODIAG-Combi 9% [2-15] 6% [1-12] 67% [46-87] (+++) 16% [8-23] (++) 0% [0-0] 
  4	  
p-value < 0.05 = (+)  5	  
p-value < 0.01 = (++) 6	  
p-value < 0.001 = (+++) 7	  
